Agreement - August 30, 2024
Rokote Laboratories signs an agreement with 3PBIOVIAN
Rokote Laboratories Finland has selected 3PBIOVIAN as their CDMO partner for GMP manufacturing of adenovirus type 5 (Ad5) vector-based candidate expressing a modified spike protein of severe acute respiratory coronavirus 2. 3PBIOVIAN will provide Rokote Laboratories with Drug Substance and Drug Product to bring the intranasal FINCoVac 2.1 vaccine into Phase I clinical studies. The […]
Business article - July 24, 2024
AGC Biologics completes Copenhagen campus expansion
The company estimates this will create several hundred more jobs, which they will begin filling this year. The grand opening of the new facility, held on June 18th, hosted elected officials and leaders from the Danish political and life science community, including the Ministry of Taxation, the Japanese Ministry in Denmark, and the Mayor of […]
CDMO - April 15, 2024
Curida secures equity investment and appoints new CEO
Curida Holding has announced a significant growth investment from Signet Healthcare Partners, a New York-based healthcare private equity firm together with existing shareholders, Canica, Investinor, Klaveness Marine and Farvatn Private Equity. This investment will enable Curida to accelerate its expansion plans, including enhancing facility capabilities and growing its industry position, it states. The total investment […]
Acquisition - April 10, 2024
Recipharm sell seven of its sites to Blue Wolf Capital Partners
The US-based private equity firm has committed to acquire Recipharm’s sites in Solna, Strängnäs, Höganäs, Karlskoga and Uppsala OTC Development in Sweden, Pessac in France, and Parets in Spain. The colleagues at those sites form a new organisation under the leadership of Peter Kruger, Group Managing Director, states Recipharm. “The consolidation of our sites network […]
Acquisition - February 6, 2024
Novo Holdings to acquire Catalent
Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at USD 16.5 billion on an enterprise value basis. Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, will acquire all outstanding shares of CDMO Catalent for USD 63.50 per share […]
CDMO - January 15, 2024
Sneak peak from the hub – how does it work?
Charlotte Fribert (CF), CEO of Toleranzia, and Niranjan Sardesai (NS), founder and CEO of Geneos Therapeutics, were among the delegates partaking in the future of advanced biologics conference (September 2023) that already tried out the innovation hub approach for real. In a brief interview, Helena Strigård gathered some of their thoughts. The projects that your […]
